Form 8-K - Current report:
SEC Accession No. 0001193125-24-172218
Filing Date
2024-06-28
Accepted
2024-06-28 16:00:32
Documents
15
Period of Report
2024-06-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d129014d8k.htm   iXBRL 8-K 47089
2 EX-3.1 d129014dex31.htm EX-3.1 8327
3 EX-10.1 d129014dex101.htm EX-10.1 4530
  Complete submission text file 0001193125-24-172218.txt   197468

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA algs-20240627.xsd EX-101.SCH 2836
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20240627_lab.xml EX-101.LAB 19483
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20240627_pre.xml EX-101.PRE 12144
18 EXTRACTED XBRL INSTANCE DOCUMENT d129014d8k_htm.xml XML 3987
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 241085434
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)